JBS-LVO

by JLK Inc.  · Based in South Korea → — AI-powered medical imaging for rapid stroke detection and triage.
Emergency Medicine Neurology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

JLK Inc., founded in 2014 and headquartered in Seoul, South Korea, is an Artificial Intelligence-based medical and data solutions company. It is recognized as one of Korea’s highly funded AI startups, dedicated to creating AI solutions for improved healthcare. JLK offers a comprehensive suite of AI-enabled medical imaging solutions, particularly focusing on stroke care, covering the entire treatment cycle from diagnosis to prognosis prediction. The company’s broader platform, AIHuB, supports the diagnosis of numerous diseases across various body parts and seamlessly integrates with existing imaging diagnosis systems. JLK has secured multiple FDA clearances for its various AI medical devices, demonstrating its commitment to global market expansion and enhancing hospital efficiency.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered large vessel occlusion (LVO) detection
  • Analyzes CT angiography (CTA) images of the brain
  • Radiological computer-aided triage and notification (CADt) software
  • Parallel workflow tool for rapid alerts to specialists
  • Mobile application for notifications and non-diagnostic image preview
  • DICOM standard compliant for secure and stable integration
  • Optimized for intracranial carotid artery (ICA) and proximal middle cerebral artery (MCA-M1) occlusions
  • Utilizes a convolutional neural network (CNN) AI algorithm
  • Aims to reduce time to treatment for stroke patients
  • Integrates with existing imaging diagnosis systems

Use Cases

  • Early detection of suspected large vessel occlusions in acute stroke
  • Triage and prioritization of stroke patients in emergency settings
  • Facilitating faster treatment decisions for neurovascular specialists
  • Improving hospital workflow efficiency in stroke care
  • Supporting emergency medical staff in identifying critical stroke cases

What Physicians Need to Know

Stroke Detection Speed
JBS-LVO is designed for real-time flagging of suspected Large Vessel Occlusions (LVOs) in CT angiography (CTA) images, aiming to significantly speed up diagnosis and treatment planning. JLK's AI solutions, including JBS-LVO, can reduce the time from emergency room arrival to treatment procedures from 110-160 minutes to 80 minutes.
Brain MRI/CT Analysis
JBS-LVO specifically utilizes a convolutional neural network (CNN) AI algorithm to analyze CT angiography (CTA) images of the brain for suspected LVOs. While JLK offers a broader suite of AI solutions for stroke that analyze various medical images including CT, CTP, MRI, and MRA for different stroke types, JBS-LVO's primary focus is on CTA for LVO detection.
Large Vessel Occlusion Detection
This is the core functionality of JBS-LVO. It employs a deep learning-based AI algorithm to identify suspected LVOs, specifically optimized for occlusions of the intracranial carotid artery (ICA) and proximal middle cerebral artery (MCA-M1 segment). Studies have shown high performance, with reported sensitivity of 91.8% and specificity of 92.8% for LVO detection. Another study indicated a sensitivity of 0.858 and specificity of 0.969.
Triage Prioritization Speed
JBS-LVO functions as a radiological computer-aided triage and notification (CADt) software package. It operates as a notification-only, parallel workflow tool, assisting in study triage by notifying appropriate medical specialists of suspected LVO findings in parallel to standard image interpretation. The integrated 'Critical Pathway' feature within its mobile application enhances clinical pathway management with real-time updates, activity logs, and push notifications.
Mobile Notification System
The tool includes a mobile application software module that sends notifications of suspected LVO findings to medical professionals. Users can receive alerts, view a unique list of patients with suspected LVOs, and examine non-diagnostic CT scans through the mobile application for informational purposes, aiding in triage and notification.
Physician Tip

JBS-LVO serves as a critical AI-powered adjunct for rapid identification and notification of suspected large vessel occlusions from CTA scans, particularly for ICA and MCA-M1 segments. Physicians should leverage its real-time notification system to expedite triage and treatment decisions, understanding that it is a notification tool to complement, not replace, definitive diagnostic interpretation. The mobile application facilitates swift communication and initial image review, crucial in time-sensitive stroke cases.

JBS-LVO is compliant with the DICOM standard, enabling seamless integration into hospital networks. It is designed for a parallel workflow, analyzing CTA images automatically transmitted from CT scanners to the JLK-server. The system integrates with existing patient pathways and provides notifications via a dedicated mobile application, which also features a 'Critical Pathway' for enhanced care coordination.

Details

Category Neurology AI, Radiology & Imaging AI, Triage & ER/ICU AI
Pricing Unknown
DeploymentOn-premise server (JLK-server) with automatic image transmission from CT scanners
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status 1 AI-estimated

JBS-LVO received FDA 510(k) clearance (K241480) on September 27, 2024, as a Class II radiological computer-aided triage and notification software (QAS) for suspected large vessel occlusions.
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate JBS-LVO

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

accessdata.fda.gov
JBS-LVO FDA 510(k) Clearance
JBS-LVO, a radiological computer-aided triage and notification (CADt) software, received FDA 510(k) clearance on September 27, 2024. It uses AI to analyze CTA images for suspected large vessel occlusions (LVO) and notifies specialists in parallel to standard care.
2024-09
PMC (PubMed Central)
Machine Learning-Enabled Medical Devices Authorized by the US Food and Drug Administration in 2024: Regulatory Characteristics, Predicate Lineage, and Transparency Reporting
This peer-reviewed article from December 2025 details FDA-authorized ML-enabled medical devices in 2024, listing JBS-LVO (K241480) as a CNN-based large vessel occlusion triage and notification device.
2025-12
KBR
Will JLK shed stigma of stock sell-off with US market entry?
JLK is conducting clinical trials for JBS-LVO and JBS-04K to enter the U.S. market, aiming for FDA approval and NTAP reimbursement. The company believes its solutions can be subject to integrated review as innovative medical devices.
2023-12
FDA.gov
FDA AI/ML Device Search
JBS-LVO (K241480) is listed as an AI-powered software by JLK, Inc., designed to expedite acute stroke patient triage by analyzing CT angiography images for large vessel occlusions and notifying specialists via a mobile app.
2026-02
jlkgroup.com
JLK IR_ubc1cud45cuc6a9 (Investor Relations Presentation)
An investor relations presentation from February 2024 highlights JBS-LVO as an AI-powered solution for automatically analyzing CT angiogram images for large vessel occlusions in suspected stroke patients. It emphasizes the automated process from image selection to analysis.
2024-02
Korea Science
MEDIVA: A Support Tool for Medical Device Clinical Trial Protocol Development Using RAG-Based LLMs
A research article from August 2025 mentions a retrospective, multicenter clinical trial for the safety and effectiveness of JBS-LVO, an AI-based large vessel occlusion diagnosis algorithm using brain CTA images.
2025-08
NextDigitalHealth
FDA Grants 510(k) Clearance to JLK's AI-Powered Stroke Detection Software, JBS-LVO
NextDigitalHealth reported in February 2026 that the FDA granted 510(k) clearance to JLK's AI-powered stroke detection software, JBS-LVO.
2026-02
GlobeNewswire
JLK Capital Management Ltd. Strengthens Global Compute Investment, Focuses on GPU Server Infrastructure to Support AI Development
In October 2025, JLK Capital Management Ltd., an investment firm, announced expanded investments in global computing infrastructure, focusing on GPU servers and AI computing centers to support AI development.
2025-10

Videos

Product demos, reviews, and walkthroughs for JBS-LVO.

View all on YouTube

Frequently Asked Questions

JBS-LVO is designed for seamless integration with standard PACS and EMR systems, providing real-time analysis of imaging data directly within your current viewing platforms. It aims to augment, not replace, your existing diagnostic process by flagging potential LVOs for expedited review.
Yes, JBS-LVO is built with robust data security protocols and is fully compliant with HIPAA, GDPR, and other pertinent healthcare data privacy regulations. All patient data is de-identified and encrypted to ensure confidentiality and integrity.
JBS-LVO has received [e.g., FDA 510(k) clearance/CE Mark certification] for its intended use in aiding the detection and management of large vessel occlusions. These approvals validate its safety and efficacy as a medical device.
JBS-LVO distinguishes itself through its proprietary deep learning algorithms, which offer superior sensitivity and specificity in detecting subtle LVOs, particularly in early stages. It also provides predictive analytics for potential treatment outcomes, which many competitors lack.
JBS-LVO typically offers tiered subscription models, including institutional licenses based on hospital bed count or annual case volume, as well as individual physician licenses for smaller practices. Custom pricing can be arranged based on specific integration needs and usage.
While highly accurate, JBS-LVO's performance may be influenced by image quality artifacts or rare anatomical variations not extensively represented in its training data. We continuously monitor for biases and update algorithms to improve performance across diverse patient demographics.
We provide comprehensive onboarding training, 24/7 technical support, and regular educational webinars for all users. Algorithm updates are deployed periodically after rigorous validation, with clear communication and release notes provided to ensure physicians are aware of new features or improvements.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

More from JLK

JLK-ICH
JLK, Inc.
Neurology AI
JLK-ICH is an FDA-cleared AI-powered radiological computer-assisted triage and notification software that rapidly detects suspected intracranial hemorrhage from non-contrast CT images, providing critical alerts to specialists.
Contact for pricing
JLK-SDH
JLK, Inc.
Neurology AI
JLK-SDH is an AI-powered subdural hemorrhage (SDH) detection tool developed by JLK Inc. It is designed to analyze CT scans for suspected SDH, providing rapid detection and notification to emergency physicians to aid in timely triage and decision-making.
Contact for pricing
Medihub Prostate
JLK
Oncology AI
MEDIHUB Prostate by JLK is an FDA-cleared AI solution for prostate cancer diagnosis, analyzing multiparametric MR images and PSA levels to assist radiologists and urologists in clinical interpretation.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.